Is Olema Pharmaceuticals Stock a Good Investment?
Olema Pharmaceuticals Investment Advice | OLMA |
- Examine Olema Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Olema Pharmaceuticals' leadership team and their track record. Good management can help Olema Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Olema Pharmaceuticals' business and its evolving consumer preferences.
- Compare Olema Pharmaceuticals' performance and market position to its competitors. Analyze how Olema Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Olema Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Olema Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Olema Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Olema Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Olema Pharmaceuticals Stock
Researching Olema Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.72. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Olema Pharmaceuticals recorded a loss per share of 2.2. The entity had not issued any dividends in recent years.
To determine if Olema Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Olema Pharmaceuticals' research are outlined below:
| Olema Pharmaceuticals generated a negative expected return over the last 90 days | |
| Olema Pharmaceuticals has high historical volatility and very poor performance | |
| Olema Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (129.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Olema Pharmaceuticals currently holds about 240.71 M in cash with (104.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Olema Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Olema Pharmaceuticals Given Outperform Rating at Oppenheimer |
Olema Pharmaceuticals Quarterly Accounts Payable |
|
Olema Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Olema Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Olema Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Olema Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Olema Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-10 | 2021-06-30 | -0.38 | -0.42 | -0.04 | 10 | ||
2022-02-28 | 2021-12-31 | -0.49 | -0.54 | -0.05 | 10 | ||
2021-05-11 | 2021-03-31 | -0.28 | -0.39 | -0.11 | 39 | ||
2022-08-09 | 2022-06-30 | -0.64 | -0.82 | -0.18 | 28 | ||
2022-11-08 | 2022-09-30 | -0.77 | -0.57 | 0.2 | 25 | ||
2023-08-08 | 2023-06-30 | -0.73 | -0.49 | 0.24 | 32 | ||
2021-03-17 | 2020-12-31 | -0.18 | -0.5 | -0.32 | 177 | ||
2025-03-10 | 2024-12-31 | 0.1732 | -0.51 | -0.6832 | 394 |
Olema Pharmaceuticals Target Price Consensus
Olema target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Olema Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Olema analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Olema stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Olema Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationOlema Pharmaceuticals Target Price Projection
Olema Pharmaceuticals' current and average target prices are 4.20 and 28.00, respectively. The current price of Olema Pharmaceuticals is the price at which Olema Pharmaceuticals is currently trading. On the other hand, Olema Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Olema Pharmaceuticals Market Quote on 25th of March 2025
Target Price
Analyst Consensus On Olema Pharmaceuticals Target Price
Olema Pharmaceuticals Analyst Ratings
Olema Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Olema Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Olema Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Olema Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Olema Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Olema Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Olema Pharmaceuticals backward and forwards among themselves. Olema Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Olema Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-12-31 | 1.9 M | Citadel Advisors Llc | 2024-12-31 | 1.7 M | Venbio Select Advisor Llc | 2024-12-31 | 1.7 M | Candriam Luxembourg S.c.a. | 2024-12-31 | 1.6 M | Wellington Management Company Llp | 2024-12-31 | 1.5 M | Vivo Capital, Llc | 2024-12-31 | 1.5 M | Woodline Partners Lp | 2024-12-31 | 1.4 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.3 M | Balyasny Asset Management Llc | 2024-12-31 | 1.1 M | Bain Capital Life Sciences Investors, Llc | 2024-12-31 | 7.5 M | Paradigm Biocapital Advisors Lp | 2024-12-31 | 7.3 M |
Olema Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 295.2 M.Market Cap |
|
Olema Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.35) | (0.33) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (0.32) | (0.30) |
Determining Olema Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Olema Pharmaceuticals is a good buy. For example, gross profit margin measures Olema Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Olema Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Olema Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Olema Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Olema Pharmaceuticals' management manipulating its earnings.
Evaluate Olema Pharmaceuticals' management efficiency
Olema Pharmaceuticals has return on total asset (ROA) of (0.2443) % which means that it has lost $0.2443 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3906) %, meaning that it created substantial loss on money invested by shareholders. Olema Pharmaceuticals' management efficiency ratios could be used to measure how well Olema Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of March 25, 2025, Return On Tangible Assets is expected to decline to -0.3. The current year's Return On Capital Employed is expected to grow to -0.33. At present, Olema Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 11.8 M, whereas Total Assets are forecasted to decline to about 249.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.96 | 3.73 | |
| Tangible Book Value Per Share | 6.96 | 3.73 | |
| Enterprise Value Over EBITDA | (1.44) | (1.51) | |
| Price Book Value Ratio | 0.84 | 0.88 | |
| Enterprise Value Multiple | (1.44) | (1.51) | |
| Price Fair Value | 0.84 | 0.88 | |
| Enterprise Value | 235.1 M | 223.3 M |
Olema Pharmaceuticals has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 2.118 |
Basic technical analysis of Olema Stock
As of the 25th of March, Olema Pharmaceuticals holds the Coefficient Of Variation of (898.85), variance of 20.35, and Risk Adjusted Performance of (0.09). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Olema Pharmaceuticals, as well as the relationship between them.Olema Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Olema Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Olema Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Olema Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Olema Pharmaceuticals' Outstanding Corporate Bonds
Olema Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Olema Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Olema bonds can be classified according to their maturity, which is the date when Olema Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Olin 5625 percent Corp BondUS680665AL00 | View | |
| Olin 5 percent Corp BondUS680665AK27 | View | |
| Olin 5125 percent Corp BondUS680665AJ53 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Olema Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Olema Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.21) | |||
| Mean Deviation | 3.68 | |||
| Coefficient Of Variation | (898.85) | |||
| Standard Deviation | 4.51 | |||
| Variance | 20.35 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.33) | |||
| Treynor Ratio | (0.22) | |||
| Maximum Drawdown | 22.08 | |||
| Value At Risk | (8.78) | |||
| Potential Upside | 7.2 | |||
| Skewness | (0.13) | |||
| Kurtosis | (0.16) |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.21) | |||
| Mean Deviation | 3.68 | |||
| Coefficient Of Variation | (898.85) | |||
| Standard Deviation | 4.51 | |||
| Variance | 20.35 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.33) | |||
| Treynor Ratio | (0.22) | |||
| Maximum Drawdown | 22.08 | |||
| Value At Risk | (8.78) | |||
| Potential Upside | 7.2 | |||
| Skewness | (0.13) | |||
| Kurtosis | (0.16) |
Consider Olema Pharmaceuticals' intraday indicators
Olema Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Olema Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 31688.98 | |||
| Daily Balance Of Power | (0.46) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 4.32 | |||
| Day Typical Price | 4.28 | |||
| Price Action Indicator | (0.18) | |||
| Period Momentum Indicator | (0.12) |
Olema Pharmaceuticals Corporate Filings
8K | 18th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 28th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Olema Stock media impact
Far too much social signal, news, headlines, and media speculation about Olema Pharmaceuticals that are available to investors today. That information is available publicly through Olema media outlets and privately through word of mouth or via Olema internal channels. However, regardless of the origin, that massive amount of Olema data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Olema Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Olema Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Olema Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Olema Pharmaceuticals alpha.
Olema Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Olema Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Olema Pharmaceuticals Corporate Management
| JD Moriarty | Corporate Secretary | Profile | |
| Peter Kushner | CoFounder Fellow | Profile | |
| PharmD Faltaos | VP Pharmacology | Profile | |
| Kinney Horn | Chief Officer | Profile | |
| Cyrus Harmon | Chief Director | Profile | |
| Courtney Dugan | VP Communications | Profile | |
| John Moriarty | Chief VP | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Olema Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.